•
Dec 31, 2020

ResMed Q2 2021 Earnings Report

ResMed's second-quarter results reflected continued solid performance with top-line growth and double-digit improvement in operating income and earnings per share.

Key Takeaways

ResMed Inc. reported a 9% increase in revenue to $800.0 million for the second quarter of fiscal year 2021. GAAP diluted earnings per share were $1.23, and non-GAAP diluted earnings per share were $1.41. The company saw growth in its core markets and adoption of digital health solutions.

Revenue increased by 9% year-over-year to $800.0 million.

GAAP gross margin was 57.8%, while non-GAAP gross margin expanded to 59.9%.

Net operating profit increased by 12%, and non-GAAP operating profit rose by 16%.

GAAP diluted earnings per share reached $1.23, and non-GAAP diluted earnings per share were $1.41.

Total Revenue
$800M
Previous year: $736M
+8.7%
EPS
$1.41
Previous year: $1.21
+16.5%
Gross Profit
$462M
Previous year: $427M
+8.3%
Cash and Equivalents
$256M
Previous year: $204M
+25.4%
Free Cash Flow
$135M
Previous year: $44.8M
+201.1%
Total Assets
$4.57B
Previous year: $4.35B
+5.0%

ResMed

ResMed

ResMed Revenue by Segment

ResMed Revenue by Geographic Location

Forward Guidance

No specific forward guidance was provided in the release.

Revenue & Expenses

Visualization of income flow from segment revenue to net income